EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Abstracts presented as part of the proceedings of the 2026 IBCN annual meeting

Bladder Cancer · 2026-09 · 12 (2_suppl)

DOI: 10.1177/23523735261479794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 15.09.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

APOBEC3 mutagenesis generates abundant neoantigens that should enhance immune recognition, yet many APOBEC3driven bladder cancers remain T-cell poor and resistant to immune checkpoint blockade.The tumor-intrinsic mechanisms underlying this immune-neoantigen paradox remain poorly understood.

Methods

We integrated copy-number, transcriptomic, neoantigen, single-cell, and spatial profiling data from public and in-house bladder cancer cohorts (∼600 human tumors) to identify genomic determinants of immune exclusion.Candidate mechanisms were evaluated using molecular, proteomic, imaging, and functional studies in tumor-cell and syngeneic bladder cancer models.

Results

We identified a recurrent neoantigen-high/CD8-low tumor state associated with chromosome 1q23.3amplification, present in 17% bladder tumors and enriched for APOBEC3 mutational signatures.This tumor subset exhibited suppression of antigen-presentation, cytokine, and immune-engagement programs.NECTIN4 within the 1q23.3locus was the dominant predictor of immune-neoantigen discordance and reduced T-cell infiltration.Functionally, NECTIN4 promoted a T-cell-poor microenvironment and conferred resistance to PD-1 blockade in immunogenic bladder cancer models.Mechanistically, NECTIN4 activated a DDR1-SHP2 signaling axis that suppressed STAT1 phosphorylation, resulting in reduced interferon-responsive cytokine production, antigen presentation, and immune engagement.Antibody-mediated NECTIN4 blockade reversed immune suppression and inhibited tumor growth in vivo.Long-and short-read sequencing, genomic timing, and breakpoint analyses linked APOBEC3 mutagenesis to NECTIN4 amplification events, supporting a model in which APOBEC3 activity promotes immune-evasive clones.

Conclusion

NECTIN4-driven STAT1 suppression represents a reversible mechanism of immune evasion in APOBEC3-driven bladder tumors and supports combining NECTIN4-targeted therapy with immune checkpoint blockade.

Zitieren

APA

(2026). Abstracts presented as part of the proceedings of the 2026 IBCN annual meeting. Bladder Cancer, 12(2_suppl). https://doi.org/10.1177/23523735261479794

Vancouver

Abstracts presented as part of the proceedings of the 2026 IBCN annual meeting. Bladder Cancer. 2026;12(2_suppl). doi:10.1177/23523735261479794

BibTeX
@article{euvimed2026,
  title = {Abstracts presented as part of the proceedings of the 2026 IBCN annual meeting},
  journal = {Bladder Cancer},
  year = {2026},
  volume = {12},
  number = {2_suppl},
  doi = {10.1177/23523735261479794}
}
Kostenlos starten →